Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BRII-179,Elebsiran
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : VBI Vaccines
Deal Size : $33.0 million
Deal Type : Acquisition
Brii Biosciences Announces Agreement To Acquire VBI's IP Rights In BRII-179
Details : Through the acquisition, Brii will get access to focus on the development of VBI-2601 (BRII-179), a protein-based HBV immunotherapeutic candidate intended for the treatment of chronic HBV infection.
Brand Name : VBI-2601
Molecule Type : Vaccine
Upfront Cash : $10.0 million
February 13, 2024
Lead Product(s) : BRII-179,Elebsiran
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : VBI Vaccines
Deal Size : $33.0 million
Deal Type : Acquisition
Lead Product(s) : BRII-179,VIR-2218
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : VBI Vaccines
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : VBI-2601 (BRII-179) is a novel recombinant, protein-based HBV immunotherapeutic candidate that builds upon the 3-antigen conformation of VBI’s prophylactic 3-antigen HBV vaccine candidate and is designed to target enhanced B-cell and T-cell immunity.
Brand Name : VBI-2601
Molecule Type : Vaccine
Upfront Cash : Not Applicable
September 06, 2023
Lead Product(s) : BRII-179,VIR-2218
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : VBI Vaccines
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : BRII-179
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : VBI Vaccines
Deal Size : $437.0 million
Deal Type : Expanded Collaboration
Details : Under the collaboration, Brii Bio expanded its exclusive license to VBI-2601 (BRII-179), VBI’s HBV immunotherapeutic candidate, to global rights and acquired an exclusive license for PreHevbri, VBI’s 3-antigen hepatitis B vaccine, in the Asia Pacific...
Brand Name : VBI-2601
Molecule Type : Vaccine
Upfront Cash : $15.0 million
July 05, 2023
Lead Product(s) : BRII-179
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : VBI Vaccines
Deal Size : $437.0 million
Deal Type : Expanded Collaboration
Lead Product(s) : BRII-693
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Qpex Biopharma
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Brii Bio will acquire exclusive global rights for the development and commercialization of QPX9003 (BRII-693), a novel synthetic lipopeptide in development for the treatment of MDR/XDR gram-negative bacterial infections, to expand from its existing right...
Brand Name : QPX9003
Molecule Type : Peptide
Upfront Cash : $24.0 million
June 25, 2023
Lead Product(s) : BRII-693
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Qpex Biopharma
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : BRII-297
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BRII-297 is a gamma-aminobutyric acid A receptor positive allosteric modulator and first-of-its-kind long-acting injectable therapeutic candidate in development for the treatment of various anxiety and depressive disorders.
Brand Name : BRII-297
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 31, 2023
Lead Product(s) : BRII-297
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Islatravir Prodrug,Rilpivirine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BRII-732/BRII-778 combination is currently in Phase 1 development in the U.S. as therapy for human immunodeficiency virus infection that can be administered on weekly basis potentially preferable choice for patients currently receiving once-daily treatme...
Brand Name : BRII-732
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 19, 2022
Lead Product(s) : Islatravir Prodrug,Rilpivirine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Rilpivirine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Brii Biosciences Presents Data on Novel HIV Therapeutics at IDWeek 2022
Details : BRII-778 (rilpivirine), a modified-release Oral Formulation is being evaluated in the early-stage clinical trials studies for the treatment of patients suffering from HIV-infections.
Brand Name : BRII-778
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 19, 2022
Lead Product(s) : Rilpivirine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Amubarvimab,Romlusevimab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Independent lab results demonstrate that the BRII-196 (amubarvimab/romlusevimab) combination therapy retains neutralizing activity against currently dominant COVID-19 strains, as previously demonstrated with all variants of concern to date.
Brand Name : BRII-196
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 26, 2022
Lead Product(s) : Amubarvimab,Romlusevimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Amubarvimab,Romlusevimab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : TSB Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BRII-196 (amubarvimab) and romlusevimab are non-competing SARS-CoV-2 mAB derived from convalesced COVID-19 patients, have been specifically engineered to reduce risk of antibody-dependent enhancement and prolong plasma half-lives for potentially more dur...
Brand Name : BRII-196
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 07, 2022
Lead Product(s) : Amubarvimab,Romlusevimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : TSB Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Amubarvimab,Romlusevimab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Studies conducted by independent labs demonstrated the BRII-196 (amubarvimab) in combination with romlusevimab retains neutralizing activity against COVID-19 Omicron variant.
Brand Name : BRII-196
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 09, 2022
Lead Product(s) : Amubarvimab,Romlusevimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?